Efficacy and safety of mirabegron for the treatment of neurogenic detrusor overactivity resulting from traumatic spinal cord injury: A prospective study.

To assess the clinical, urodynamic efficacy, and safety of mirabegron in patients with neurogenic detrusor overactivity (NDO) consequent to traumatic spinal cord injury (SCI). This prospective cohort study was performed between January 2018 and July 2019 and included adult patients with stable traumatic suprasacral SCI, performing clean intermittent catheterization (CIC), and demonstrating NDO on urodynamic […]

Mediterranean Diet May Affect the Progression of Prostate Cancer for Men on Active Surveillance

San Francisco, CA (UroToday.com) — In a study to examine a Mediterranean diet in relation to prostate cancer progression in men on active surveillance, researchers from The University of Texas MD Anderson Cancer Center found that men with localized prostate cancer who reported a baseline dietary pattern that more closely follows the key principles of a Mediterranean-style […]

Overall Survival and Other Secondary Endpoint Data Gain FDA Approval for NUBEQA® (darolutamide) Label

Phase III data showed treatment with NUBEQA resulted in a 31% reduction in risk of death, with a statistically significant improvement in overall survival (OS) compared to placebo (HR=0.69, 95% CI 0.53-0.88; p=0.003), giving men with non-metastatic castration-resistant prostate cancer (nmCRPC) the opportunity to extend their lives1 Time to pain progression, a key secondary endpoint, […]

Preference for Sleep Management Strategies Among Prostate Cancer Patients: An Aotearoa/New Zealand Perspective – Beyond the Abstract

Insomnia is commonly experienced by prostate cancer (PCa) patients.1-3 Despite this fact, there is limited research on management strategies that PCa patients prefer to use to improve their sleep. In this study, we asked PCa patients in Aotearoa New Zealand about their sleep quality, as well as the strategies they prefer to use for improving […]

X